Con estos parámetros, no todos pueden ser líderes.
There is no pharmacological reason to expect that commonly prescribed medicinal products used in the treatment of asthma will interact with omalizumabLiterature Literature
HPS está convencido de que su posición en el mercado debe ser “líder” y no “seguidor”.
The reasons for this are not just related to the countries concerned but are also a reflection of the growing scepticism about enlargement in certain political quarters.Common crawl Common crawl